The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer

Rebecca R. Pharaon, Yan Xing, Mark Agulnik, Victoria M. Villaflor

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

A subset of head and neck cancers arising in the oropharynx and the nasopharynx are associated with human papillomavirus or Epstein–Barr virus. Unfortunately, limited treatment options exist once patients develop recurrent or metastatic disease in these cancers. Interest has risen in utilizing novel strategies including combination immune checkpoint inhibitors, vaccines, and adoptive cellular therapy, to improve treatment response and outcomes. Several ongoing studies are investigating the potential to overcome resistance to standard of care chemoradiation therapy with monotherapy or combination immunotherapy strategies in these viral-associated head and neck cancers.

Original languageEnglish (US)
Article number649963
JournalFrontiers in Oncology
Volume11
DOIs
StatePublished - Jul 16 2021

Keywords

  • Epstein–Barr virus
  • head and neck cancer
  • human papillomavirus
  • immunotherapy
  • nasopharyngeal carcinoma
  • oropharyngeal squamous cell carcinoma
  • viral-associated cancers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer'. Together they form a unique fingerprint.

Cite this